Exchange Traded Concepts LLC Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP

Exchange Traded Concepts LLC purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 8,466 shares of the specialty pharmaceutical company’s stock, valued at approximately $775,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the first quarter worth $28,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of ANI Pharmaceuticals by 4,636.4% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after acquiring an additional 510 shares in the last quarter. Newbridge Financial Services Group Inc. increased its holdings in shares of ANI Pharmaceuticals by 200.0% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after acquiring an additional 400 shares during the last quarter. State of Wyoming acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $50,000. Finally, Emerald Advisers LLC raised its stake in shares of ANI Pharmaceuticals by 414.8% in the 2nd quarter. Emerald Advisers LLC now owns 1,256 shares of the specialty pharmaceutical company’s stock valued at $82,000 after acquiring an additional 1,012 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Truist Financial upped their target price on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. HC Wainwright upped their price objective on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Guggenheim lifted their target price on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, November 10th. JPMorgan Chase & Co. boosted their target price on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Finally, Barclays began coverage on ANI Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $102.14.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, Director Patrick D. Walsh sold 8,643 shares of ANI Pharmaceuticals stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $86.88, for a total transaction of $750,903.84. Following the sale, the director owned 61,405 shares in the company, valued at $5,334,866.40. The trade was a 12.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Renee P. Tannenbaum sold 1,800 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $81.15, for a total transaction of $146,070.00. Following the completion of the sale, the director directly owned 25,157 shares in the company, valued at $2,041,490.55. This trade represents a 6.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 28,001 shares of company stock worth $2,446,934. 11.10% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock opened at $81.38 on Tuesday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. The company has a market cap of $1.83 billion, a PE ratio of 49.93 and a beta of 0.48. The firm has a fifty day moving average price of $85.42 and a two-hundred day moving average price of $82.42. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.74 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The company had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. During the same quarter in the previous year, the firm posted $1.34 EPS. The business’s revenue was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.